International Peer-Reviewed Journal•Open Access•ISSN 2456-8880
[email protected]•+91-7433024337

Home / Current Issue / Paper 1725438

1725438 Vol 10 · Issue 5 Download Paper

Epigenetic Editing and Its Role in Disease Treatment

Dinesh Kumar S Mithun R

Subject area: Biological & Medical Sciences  ·  Area of research: Epigenetics

Abstract

Epigenetic control of gene expression involves regulation of gene expression without changing DNA sequence and encompasses various processes such as DNA methylation, histone modifications, chromatin remodeling and noncoding RNAs. Dysregulation of epigenetic regulation causes malfunction in gene expression leading to diseases such as cancer, neurological diseases, genetic diseases, metabolic diseases and inflammatory diseases. Epigenetic editing offers a potential therapy to specifically edit epigenetic states and regulate gene expression without directly altering DNA sequence in order to treat diseases. CRISPR/dCas9-based technology allows targeted delivery of epigenetic effector proteins to the genome site which enables targeted DNA methylation, DNA demethylation and histone modification. Such technology is capable of rescuing repressed genes, blocking deleterious gene expression and restoring physiological cell functions. However, some issues need to be addressed before epigenetic editing could become a promising therapy; off-targeting, delivery effectiveness, editing specificity, duration of epigenetic alteration, immune response and safety concerns. The development of novel molecular engineering and targeted drug delivery technologies will facilitate the use of epigenetic editing for medical purposes. Therefore, epigenetic editing is a new promising strategy for disease treatment that may contribute to the emergence of precision medicine.

Keywords

epigenetic editing, CRISPR, DNA methylation, histone modification, gene regulation, cancer, gene therapy, disease treatment

References

[1] McCutcheon SR, Rohm D, Iglesias N, et al. Epigenome editing technologies for discovery and medicine. Nature Biotechnology. 2024;42:1199–1217.

[2] Thakore PI, Black JB, Hilton IB, et al. Editing the epigenome: technologies for programmable transcription and epigenetic modulation. Nature Methods. 2016;13:127–137.

[3] Portela A, Esteller M. Epigenetic modifications and human disease. Nature Biotechnology. 2010;28:1057–1068.

[4] Robertson KD. DNA methylation and human disease. Nature Reviews Genetics. 2005;6:597–610.

[5] Zhao S, Allis CD, Wang GG. The language of chromatin modification in human cancers. Nature Reviews Cancer. 2021;21:413–430.

[6] Smith ZD, Hetzel S, Meissner A. DNA methylation in mammalian development and disease. Nature Reviews Genetics. 2025.

[7] Wu X, Zhang Y. TET-mediated active DNA demethylation: mechanism, function and beyond. Nature Reviews Genetics. 2017;18:517–534.

[8] Millán-Zambrano G, et al. Histone post-translational modifications—cause and consequence of genome function. Nature Reviews Genetics. 2022;23:563–580.

[9] Li E. Chromatin modification and epigenetic reprogramming in mammalian development. Nature Reviews Genetics. 2002;3:662–673.

[10] Hananya N, Koren S, Muir TW. Interrogating epigenetic mechanisms with chemically customized chromatin. Nature Reviews Genetics. 2024;25:255–271.

[11] McCutcheon SR, Rohm D, Iglesias N, et al. Epigenome editing technologies for discovery and medicine. Nature Biotechnology. 2024;42:1199–1217.

[12] Villiger L, Joung J, Koblan L, et al. CRISPR technologies for genome, epigenome and transcriptome editing. Nature Reviews Molecular Cell Biology. 2024;25:464–487.

[13] Epigenome editing for targeted DNA (de)methylation: a new perspective in modulating gene expression. 2024.

[14] Goell JH, Hilton IB. CRISPR/Cas-based epigenome editing: advances, applications, and clinical utility. Trends in Biotechnology. 2021;39:678–691.

[15] McCutcheon SR, et al. Epigenome editing technologies for discovery and medicine. Nature Biotechnology. 2024;42:1199–1217.

[16] Mabe NW, et al. Pharmacological targeting of the cancer epigenome. Nature Cancer. 2024;5:844–865.

[17] Sharma R, et al. The role of epigenetic mechanisms in autoimmune, neurodegenerative, cardiovascular, and imprinting disorders. Mini-Reviews in Medicinal Chemistry. 2022;22:1977–2011.

[18] Grodzka O, et al. Diagnostic and prognostic value of epigenetic markers in neurological diseases. Cellular and Molecular Neurobiology. 2026.

[19] Keating ST, El-Osta A. Metaboloepigenetics in cancer, immunity, and cardiovascular disease. Cardiovascular Research. 2023;119:357–370.

[20] Epigenetic regulation and molecular mechanisms in cardiovascular diseases: a review of recent advances and therapeutic implications. 2026.

[21] McCutcheon SR, Rohm D, Iglesias N, et al. Epigenome editing technologies for discovery and medicine. Nature Biotechnology. 2024;42:1199–1217.

[22] Villiger L, Joung J, Koblan L, et al. CRISPR technologies for genome, epigenome and transcriptome editing. Nature Reviews Molecular Cell Biology. 2024;25:464–487.

[23] Cappelluti MA, et al. Durable and efficient gene silencing in vivo by hit-and-run epigenome editing. Nature. 2024;627:416–423.

[24] Minton K. Epigenetic editing works like a CHARM. Nature Reviews Genetics. 2024;25:600.

[25] McCutcheon SR, Rohm D, Iglesias N, et al. Epigenome editing technologies for discovery and medicine. Nature Biotechnology. 2024;42:1199–1217.

[26] Madigan V, Zhang F, Dahlman JE. Drug delivery systems for CRISPR-based genome editors. Nature Reviews Drug Discovery. 2023;22:875–894.

[27] Cappelluti MA, et al. Durable and efficient gene silencing in vivo by hit-and-run epigenome editing. Nature. 2024;627:416–423.

[28] McCutcheon SR, Rohm D, Iglesias N, et al. Epigenome editing technologies for discovery and medicine. Nature Biotechnology. 2024;42:1199–1217.

[29] Villiger L, Joung J, Koblan L, et al. CRISPR technologies for genome, epigenome and transcriptome editing. Nature Reviews Molecular Cell Biology. 2024;25:464–487.

[30] Mabe NW, et al. Pharmacological targeting of the cancer epigenome. Nature Cancer. 2024;5:844–865.

[31] McCutcheon SR, Rohm D, Iglesias N, et al. Epigenome editing technologies for discovery and medicine. Nature Biotechnology. 2024;42:1199–1217.

[32] Portela A, Esteller M. Epigenetic modifications and human disease. Nature Biotechnology. 2010;28:1057–1068.

[33] Villiger L, Joung J, Koblan L, et al. CRISPR technologies for genome, epigenome and transcriptome editing. Nature Reviews Molecular Cell Biology. 2024;25:464–487.

How to cite this paper

Dinesh Kumar S, Mithun R "Epigenetic Editing and Its Role in Disease Treatment" Iconic Research And Engineering Journals Volume 10 Issue 5 2026 Page 4433-4441
Dinesh Kumar S, Mithun R "Epigenetic Editing and Its Role in Disease Treatment" Iconic Research And Engineering Journals, vol. 10, no. 5, Nov. 2026
Dinesh Kumar S, Mithun R (2026). Epigenetic Editing and Its Role in Disease Treatment. Iconic Research And Engineering Journals, 10(5).
Dinesh Kumar S, Mithun R "Epigenetic Editing and Its Role in Disease Treatment" Iconic Research And Engineering Journals, vol. 10, no. 5, Nov. 2026.
@article{1725438,
      author = {Dinesh Kumar S, Mithun R},
      title = {Epigenetic Editing and Its Role in Disease Treatment},
      journal = {Iconic Research And Engineering Journals},
      year = {2026},
      volume = {10},
      number = {5},
      pages = {4433-4441},
      issn = {2456-8880},
      url = {https://www.irejournals.com/formatedpaper/1725438.pdf},
      abstract = {Epigenetic control of gene expression involves regulation of gene expression without changing DNA sequence and encompasses various processes such as DNA methylation, histone modifications, chromatin remodeling and noncoding RNAs. Dysregulation of epigenetic regulation causes malfunction in gene expression leading to diseases such as cancer, neurological diseases, genetic diseases, metabolic diseases and inflammatory diseases. Epigenetic editing offers a potential therapy to specifically edit epigenetic states and regulate gene expression without directly altering DNA sequence in order to treat diseases. CRISPR/dCas9-based technology allows targeted delivery of epigenetic effector proteins to the genome site which enables targeted DNA methylation, DNA demethylation and histone modification. Such technology is capable of rescuing repressed genes, blocking deleterious gene expression and restoring physiological cell functions. However, some issues need to be addressed before epigenetic editing could become a promising therapy; off-targeting, delivery effectiveness, editing specificity, duration of epigenetic alteration, immune response and safety concerns. The development of novel molecular engineering and targeted drug delivery technologies will facilitate the use of epigenetic editing for medical purposes. Therefore, epigenetic editing is a new promising strategy for disease treatment that may contribute to the emergence of precision medicine.},
      keywords = {epigenetic editing, CRISPR, DNA methylation, histone modification, gene regulation, cancer, gene therapy, disease treatment},
      month = {November},
  }